CRMD
CorMedix·NASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
Signals Analysis
Bullish signal 4
Bearish signal 1
Consensus Rating "Strong Buy"
Ample Liquidity
High Gross Profit Margin
Significant Net Income Growth
EPS Below Expectations
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About CRMD
Cormedix Inc.
A biopharmaceutical company developing therapeutic products for cardiovascular and renal diseases
300 Connell Drive, Suite 4200, Berkeley Heights, NJ 07922
--
CorMedix Inc., was incorporated in Delaware on July 28, 2006. The Company is a biopharmaceutical company focused on the development and commercialization of therapeutic products for the prevention and treatment of life-threatening diseases and conditions. The company's main focus is the commercialization of its lead product, DefenCath, in the United States. The company has licensed the development and commercialization of DefenCath worldwide. The name DefenCath is an American proprietary name approved by the U.S. Food and Drug Administration (FDA).
Earnings Call
Q1/2025
Estimate EPS0.25
Actual EPS0.3
Estimate Revenue36.00M
Actual Revenue39.10M
CorMedix's Q1 2025: Unraveling Contradictions in LDO Implementation, Patient Growth, and Partnerships
May 07,2025 02:41
Earnings Decrypt
Earnings Decrypt
Q3/2025
Estimate EPS0.63
Actual EPS1.26
Estimate Revenue86.02M
Actual Revenue104.28M
CorMedix's Q3 2025: Key Contradictions Emerge on LDO Patient Rollout, Medicare Advantage Impact, and DefenCath Pricing Dynamics
Nov 12,2025 11:01
Earnings Decrypt
Earnings Decrypt
Company Financials
EPS
CRMD has released its 2025 Q3 earnings. EPS was reported at 1.26, versus the expected 0.63, beating expectations. The chart below visualizes how CRMD has performed over recent quarters, highlighting trends in earnings surprises.
Revenue & Expenses
CRMD has released its 2025 Q3 earnings report, with revenue of 104.28M, reflecting a YoY change of 810.22%, and net profit of 108.56M, showing a YoY change of 4009.63%. The Sankey diagram below clearly presents CRMD's revenue sources and cost distribution.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
